indeloxazine has been researched along with Prostatic Hyperplasia in 1 studies
indeloxazine: RN given refers to parent cpd without isomeric designation
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horita, H | 1 |
| Kumamoto, Y | 1 |
| Satoh, Y | 1 |
| Suzuki, N | 1 |
| Wada, H | 1 |
| Shibuya, A | 1 |
| Adachi, H | 1 |
| Kurohata, T | 1 |
| Tsukamoto, T | 1 |
1 trial available for indeloxazine and Prostatic Hyperplasia
| Article | Year |
|---|---|
[The preventive effect of indeloxazine hydrochloride to the sexual dysfunction caused by anti-androgenergic agent (allylestrenol)].
Topics: Aged; Allylestrenol; Androgen Antagonists; Humans; Male; Middle Aged; Morpholines; Prostatic Hyperpl | 1995 |